MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

U.S. stocks rose in early trading Wednesday as Wall Street weighed the latest developments in the Trump administration’s bid ...

Musk already facing falling global sales at his EV maker Tesla and embroiled in war of words with US President Donald Trump ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th ...

Applied Clinical Trials is the thought leader in pharmaceutical drug development operations and clinical trial design, management, and monitoring.

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Merck's multiple sclerosis drug evobrutinib didn't meet a key goal in late-stage trials. The German pharmaceutical company's phase 3 clinical trials for the drug did not achieve their primary ...

Merck KGaA’s shares fell around 13% after its multiple sclerosis drug evobrutinib didn’t meet a key goal in late-stage trials.

Now, Merck has published phase 3 data in MS. And the news is bad. In a pair of phase 3 trials in patients with relapsing MS, the annualized relapse rates (ARR) were almost identical in recipients ...